PharmaTher grants stock options to directors at $0.22 per share

From GlobeNewswire: 2025-01-03 17:15:00

PharmaTher Holdings Ltd. has granted 800,000 stock options to two directors at an exercise price of $0.22 per share, with a five-year term expiring on January 2, 2030. The Chairman and CEO did not receive stock options. PharmaTher is focused on developing and commercializing KETARX™ (Ketamine) for various medical needs, including anesthesia, sedation, pain, mental health, and more. The company’s forward-looking information is subject to known and unknown risks, uncertainties, and factors that may impact future events. Investors should not solely rely on forward-looking statements and consider potential risks outlined in the company’s disclosures.



Read more at GlobeNewswire: PharmaTher Announces Grant of Stock Options